北京阳光诺和药物研究股份有限公司 自愿披露关于BTP4507获得药物临床试验批准通知书的公告

Core Viewpoint - Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial application of BTP4507, aimed at treating primary hypertension patients with poor response to monotherapy [1][2]. Drug Basic Information - Drug Name: BTP4507 - Application Matter: Clinical trial registration for domestic production - Acceptance Number: CXHL2500698 - Applicants: Jiangsu Nuohuo Bitop New Drug Research Co., Ltd., Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd., Beijing Baiao Pharmaceutical Co., Ltd. - Approval Conclusion: The clinical trial application for BTP4507 meets the requirements for drug registration and is approved to proceed with clinical trials [1]. Drug Characteristics - BTP4507 is classified as a Class 2 modified new chemical drug, targeting primary hypertension patients who do not respond well to monotherapy [2]. - Current hypertension treatments include various drug types, but overall control rates remain unsatisfactory due to the complex mechanisms of hypertension [2]. - BTP4507 is a compound formulation consisting of multiple drug components with different mechanisms, designed to enhance blood pressure control through synergistic effects on various targets [2].